Evidence map›Paper›PMID 41111522›Full record

ReviewFrontiers in pharmacology2025

Exploring the pharmacokinetics, drug-likeness, and toxicological features of anticancer flavonoids: a Boulevard to explore their clinical translational potential.

Ankit Kumar Dubey, Siva Sai Chandragiri, Abin V Geevarghese, Bhupinder Kapoor, Monica Gulati, Pooja Rani, Gursharan Singh, Vivek P Chavda, Rohit Gundamaraju, Himangini Bansal and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ankit Kumar Dubey *Department of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Siva Sai Chandragiri *Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
Abin V Geevarghese *Department of Pharmacology, Faculty of Pharmacy, Karpagam Academy of Higher Education, Coimbatore, Tamil Nadu, India.
Bhupinder KapoorSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Monica GulatiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Pooja RaniSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.
Gursharan SinghDepartment of Medical Laboratory Sciences, Lovely Professional University, Phagwara, India.
Vivek P ChavdaDepartment of Pharmaceutics and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad, Gujarat, India.
Rohit GundamarajuER stress and mucosal immunology lab, School of Health Sciences, University of Tasmania, Launceston, TAS, Australia.
Himangini BansalDelhi Institute of Pharmaceutical Sciences and Research, New Delhi, India.
Rupesh K GautamDepartment of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Rajat GoyalMM College of Pharmacy, Maharishi Markandeshwar (Deemed to be) University, Mullana-Ambala, Haryana, India.
Michael P OkohDepartment of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Bairong ShenDepartment of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Rajeev K SinglaDepartment of Pharmacy and Institutes for Systems Genetics, Center for High Altitude Medicine, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Flavonoids that are widely distributed across various plant species exhibit significant anticancer activity in various preclinical and clinical studies, thus offering promising therapeutic prospects. However, a thorough understanding of their pharmacokinetic properties, drug-likeness characteristics, and safety profile is essential for the translational applicability of these molecules into clinical settings. Methods: A systematic search was carried out using various electronic databases such as PubMed Central, ScienceDirect, Clinical Registry, and Google Scholar, using different keywords like "flavonoids", "cancer", "pharmacokinetics", "toxicity", "tumor", and their combinations. Non-English literature was excluded due to language barriers, limited accessibility, non-indexing, and the risk of misinterpreting methods or results, which could compromise the accuracy and reliability of the review. Results and discussion: This review provides an in-depth overview of various mechanistic pathways, such as oxidative stress-mediated and immunomodulatory pathways, that are considered to be responsible for the anti-cancer potential of flavonoids. In addition, the pharmacokinetic properties and toxicity profile of flavonoids have been discussed, which are the crucial factors in their clinical translation. Lastly, the review briefly explores various strategies that can be adopted to improve the effectiveness of flavonoids in the treatment of cancer. Conclusion: This investigation enhances our understanding of the translational potential of flavonoid-based therapies by highlighting these essential elements, bringing us one step closer to the development of effective and safe cancer treatments.

Indexed as

admetanticancer agentsdrug toxicityflavonoidspharmacokinetics

Identifiers

PMID41111522
PMCPMC12531246

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.